Future directions in therapeutic interventions for conjunctival inflammatory disorders

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 5, 2007, Pages 450-453

  Pflugfelder, Stephen C ^a,c   Stern, Michael E ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

^c CULLEN EYE INSTITUTE   (United States)

Author keywords

Allergic conjunctivitis; Atopic conjunctivitis; Keratoconjunctivitis sicca; Vernal conjunctivitis

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CYCLOSPORIN A; EPINASTINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; KETOTIFEN; LEVOCABASTINE; OLOPATADINE; TACROLIMUS;

ALLERGIC CONJUNCTIVITIS; ATOPIC KERATOCONJUNCTIVITIS; CONJUNCTIVITIS; DRUG EFFECT; DRUG EFFICACY; DRY EYE; EYE ALLERGY; GLAUCOMA; HUMAN; IMMUNE RESPONSE; KERATOCONJUNCTIVITIS SICCA; NONHUMAN; OCULAR FIBROSIS; OCULAR PRURITUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; VERNAL CONJUNCTIVITIS;

ANIMALS; CONJUNCTIVA; CONJUNCTIVITIS; CONJUNCTIVITIS, ALLERGIC; CYTOKINES; DRY EYE SYNDROMES; HUMANS;

EID: 34548677481     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282ef69e3     Document Type: Review

References (26)

1. Finegold I, Granet DB, D'Arienzo PA, Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clin Therapeut 2006; 28:1630-1638.
2. Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependant allergic conjunctivitis. Br J Ophthalmol 2006; 90:461-464.
3. Aude Pauly A, Brignole-Baudouin F, Guenoun J-M, et al. Comparative study of topical antiallergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN-γ and toxicological profiles. Graefe's Arch Clin Esp Ophthalmol 2007; 245:534-546. This study found that many of the combination antihistamine/mast cell stabilizers have antiinflammatory properties.
4. Fukushima A, Yamaguchi T, Ishida W, et al. Cyclosporine A inhibits eosinopilic infiltration into the conjunctiva mediated by type IV allergic reactions. Clin Exp Ophthalmol 2006; 34:347-353.
5. Fukushima A, Sumi T, Fukuda K, et al. Antibodies to T-cell Ig and mucin domain-containing proteins (Tim)-1 and -3 suppress the induction and progression of murine allergic conjunctivitis. Biochem Biophys Res Commun 2007; 353:211-216. The costimulatory molecules Tim 1 and 3 were found to modulate experimental allergic conjunctivitis in an IFN-γ-dependent manner.
6. Fukushima A, Sumi T, Fukuda K, et al. Interleukin 10 and transforming growth factor β contribute to the development of experimentally induced allergic conjunctivitis in mice during the effector phase. Br J Ophthalmol 2006; 90: 1535-1541. The Th2 cytokines IL-10 and TGF-β were found to potentiate certain aspects of allergic conjunctivitis.
7. Fukushima A, Yamaguchi T, Ishida W, et al. Role of VLA-4 in the development of allergic conjunctivitis in mice. Molecular Vision 2006; 12:310-317. This report indicates that blockade of VCAM-1 or its ligand VLA-4 prevents the development of allergic conjunctivitis.
8. Sumi T, Fukushima A, Fukuda K, et al. Thymus-derived CD4+ CD25+ T cells suppress the development of murine allergic conjunctivitis. Int Arch Allergy Immunol 2007; 143:276-281.
9. Stumpf T, Luqmani N, Sumich P, et al. Systemic Tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea 2006; 25:1147-1149.
10. Dogru M, Okada N, Asano-Kato N, et al. Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis. Clin Exp Allergy 2006; 36:1556-1565.
11. Malvitte L, Montange T, Vejux A, et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br J Ophthalmol 2007; 91:29-32. Chronic treatment with BAC-preserved glaucoma treatments results in ocular surface inflammation. This suggests the potential benefit of using nonpreserved formulations.
12. Barton K, Monroy D, Nava A, Pflugfelder SC. Inflammatory cytokines in tears of patients with ocular rosacea. Ophthalmology 1997; 104:1868-1874.
13. Afonso A, Sobrin L, Monroy DC, et al. Tear fluid gelatinase B activity correlates with IL-1α concentration and fluorescein tear clearance. Invest Ophthalmol Vis Sci 1999; 40:2506-2512.
14. Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004; 111:2186-2192.
15. Hong S, Lee CS, Seo KY, et al. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol 2006; 142: 185-186.
16. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between ocular surface and lacrimal glands. Cornea 1998; 17: 584-589.
17. Mrugacz M, Zak J, Bakunowicz-Lazarczyk A, et al. ICAM-1 expression on conjunctival epithelial cells in patients with cystic fibrosis. Cytometry B Clin Cytom 2007; 72:204-208. Similar to other dry eye diseases, dry eye associated with cystic fibrosis stimulates production of the adhesion molecule ICAM-1 by the conjunctival epithelium.
18. Mrugacz M, Zak J, Bakunowicz-Lazarczyk A, et al. Flow cytometric analysis of HLA-DR antigen in conjunctival epithelial cells of patients with cystic fibrosis. Eye 2006; 19 May [Epub ahead of print]. Similar to other dry eye diseases, dry eye associated with cystic fibrosis stimulates production of the immune activation molecule HLA-DR by the conjunctival epithelium.
19. Rolando M, Barabino S, Mingari C, et al. Distribution of conjunctival HLA-DR expression and the pathogenesis of damage in early dry eyes. Cornea 2005; 24:951-954.
20. Pisella PJ, Brignole F, Debbasch C, et al. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology 2000; 107:1841-1849.
21. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea 2007; 26:42-46.
22. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006; 83:526-535. Indicates that doxycycline, an agent that has been used to treat ocular surface diseases for decades, has potent antiinflammatory effects.
23. Li DQ, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res 2006; 82:588-596.
24. Ah-Chan JJ, Molteno AC, Bevin TH. Anti-inflammatory fibrosis suppression in threatened trabeculectomy bleb failure. Arch Ophthalmol 2006; 124:60. The findings indicate that inflammation is a risk factor for failure of glaucoma filtering blebs.
25. Enriquez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci 2006; 47:1416-1425. This is an exciting nanoparticle technology for delivery of therapeutic agents to the corneal and conjunctival epithelia.
26. Gomes dos Santos AL, Bochot A, Doyle A, et al. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. J Control Release 2006; 112:369-381.